Watch Ticker

BioAtla, Inc. Common Stock

Go to BioAtla, Inc. Common Stock Website

$0.38

0.03 (7.14%)

Live

Previous Close

$0.3746

Day Range

$0.3557 - $0.3789

Previous Day Range

$0.333 - $0.36

Market Cap

$20.4 million USD

Day Vol.

409404

Previous Day Vol.

348225

Currency

USD

Primary Exchange

Nasdaq

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbot...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Richard Waldron - BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

BioAtla, a clinical-stage biotechnology company, will host a conference call on August 7, 2025 to discuss its Q2 financial results and business highlights, focusing on its Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment.

Related tickers: BCAB.

Read Full Article

Bioatla, Inc. - BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

BioAtla presented first-in-human data on BA3182, a dual-conditionally binding EpCAM x CD3 bispecific T-cell engager, showing preliminary tumor reductions and a low-grade safety profile in patients with treatment-refractory metastatic adenocarcinoma.

Related tickers: BCAB.

Read Full Article

Trending Tickers

Please sign in to view